With stock value up 51 percent, is Mindray too pricey?
Ubicación actual:
> This Story

Conexión o Registro to rate this News Story
Forward Printable StoryPrint Comment




Business Affairs Homepage

Medical device industry M&A topped $5 billion in July: Analysis At $28 billion, global M&A activity is up 108 percent year-on-year

Philips execs knew of alleged bribes in Brazil in 2010, says whistleblower Whistleblower claims he warned company and was fired 'without cause'

Is Apple health team seeing some discontent? CNBC reports high rate of departures and 'tension' among members

Siemens to acquire Corindus Vascular Robotics in $1.1 billion deal Royal currently has a 12.8 percent stake in Corindus

RadNet acquires Nulogix, opens new AI division Will develop applications for image interpretation

Health Catalyst IPO — The Signify View The industry analysts share their perspective on the announcement

Carestream completes sale of IT business to Philips in most countries Now part of Philips in 26 of 38 countries where it operates

Siemens diagnostics president to step down, new board member appointed CEO Bernd Montag will assume responsibility of the business unit

Siemens rises above $4 billion in revenue in third quarter Revenue rose by 5.8 percent compared to last year

Four tips to creating greater efficiencies in your imaging department Insights from the data obtained by Definitive Healthcare

With stock value up 51 percent, is Mindray too pricey?

por Thomas Dworetzky , Contributing Reporter
Shenzhen-based Mindray Bio-Medical Electronics has soared since going private in 2016, and is taking market share from both GE and Siemens.

And in May it got put into the MSCI China All Shares Heath Care 10/40 Index, which “captures large and mid-cap representation across China A‐shares, B‐shares, H‐shares, Red‐chips, P‐chips and foreign listings,” according to MSCI, and which “aims to reflect the opportunity set of China share classes listed in Hong Kong, Shanghai, Shenzhen and outside of China.”

Story Continues Below Advertisement

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

Its stock has risen 51 percent, making it “a top performing equity on the ChiNext board” — and that has given it a $29 billion valuation, according to Bloomberg.

But the business news agency now warns that some think it may have gone a bit too far, a little too fast, with a P/E ratio of 39, despite a Bloomberg forecast of a 20 percent revenue growth and 21 percent annual income growth from now to to 2021.

That's because the consensus price target for Mindray is 158.90 yuan, showing a possible 3.8 percent downside from present lofty stock values.

The company is “looking expensive,” although not too much so versus other China high-fliers, like Chinese soy sauce maker Foshan Haitian Flavouring & Food, Xiong Qi of Windsor Capital Management told Bloomberg.

The firm, founded in 1991, had been listed in the U.S. on the NYSE until being taken private by a subsidiary of Excelsior Union Limited for $1.9 billion in 2016, according to a company statement at the time.

The maker of in-vitro diagnostics equipment, life monitoring systems and medical imaging equipment including color ultrasound devices has been liked by institutional investors, thanks, in part, to its rising R&D investment, hitting 25.5 percent annual growth, and favorable government support as China seeks to become a bigger player in the global market, according to Bloomberg. Some of these investors include Fidelity Management, China Asset Management, and Bosera Asset Management, according to the news agency. Foreign investors now hold 13.13 million shares, a rise of 80 percent in holdings post the MSCI announcement.

At present prices, there are those who think the values are a bit high and are holding off. Dai Ming, portfolio manager of Hengsheng Asset Management Co., told Bloomberg that, “Mindray’s valuation is too high. We will wait for a pull back to get in at a more reasonable price.”
  Pages: 1 - 2 >>

Business Affairs Homepage

You Must Be Logged In To Post A Comment